# CheckMate 9DW (NCT04039607)

> A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04039607
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Hepatocellular Carcinoma
- Interventions: Nivolumab; Ipilimumab; Sorafenib; lenvatinib
- Enrollment: 732
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 64
- YouTube: 31
- Podcasts: 24

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-9dw-nct04039607

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04039607", "email": "<work email>"}; the inbox owner confirms by the emailed link.